cd152 ctla 4 apc  (Miltenyi Biotec)

Journal: Cell Reports Medicine

Article Title: Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial

doi: 10.1016/j.xcrm.2026.102638

Figure Lengend Snippet: Effect of ADT + Fc-enhanced anti-CTLA-4 on DCs (A) Violin plot of myeloid cluster frequencies as percentage of myeloid cells stratified by patient’s 2-year PSA recurrence status. No recurrence, n = 7; recurrence, n = 4. Two-tailed Student’s t test was utilized to test statistical significance. For this and all violin plots to follow, solid lines denote group medians, while dashed lines denote quartiles. (B) Kaplan-Meier curve representing time-to-PSA recurrence in patients stratified by dendritic cell frequency; 95% confidence intervals shown in the shaded areas. There was one recurrence event in DC-high patients and three recurrence events in DC-low patients. Log rank test was performed to evaluate statistical significance. (C) Schematic of pre-clinical validation experiment in the MycCaP model. (D) Percent change in tumor volume relative to baseline volume prior to ADT stratified by treatment group. Average values are represented by solid lines and standard deviations are represented by shaded areas. (E) Kaplan-Meier curve representing survival of mice shown in (D). Log rank (Mantel-Cox) test was used to evaluate statistical significance. (F) Left: supervised UMAP of live CD45 + cells from MycCaP tumors harvested following therapy as denoted in (D and E). Semi-supervised clustering was performed using FlowSOM and clusters were manually annotated according to expression of lineage-defining markers. Right: heatmap of lineage-defining markers across all clusters. Data represent geometric MFI for each marker normalized to the minimum and maximum values across all clusters. (G and H) (G) Frequency of TI-Tregs and (H) frequency of cDCs as percentage of all live CD45 + cells, stratified by treatment group. (I) Left: PaCMAP representing FlowSOM-derived cDC clusters. Clusters were manually annotated according to expression of canonical marker proteins. Right: pseudocolor representation of cDC phenotypes in PaCMAP space stratified by treatment group. (J) Violin plot representing frequency of PD-L2 + DCs as percentage of all DCs stratified by treatment group. (K) Violin plot representing frequency of CD40 + DCs as percentage of all DCs stratified by treatment group. Welch’s t test was used to assess statistical significance. Murine data shown are n = 8 mice per group and representative of two independent experiments each for survival and immune profiling studies.

Article Snippet: Anti-Human CTLA-4 (14D3) 170Er , Standard BioTools , Cat# 3170005B.

Techniques: Two Tailed Test, Biomarker Discovery, Expressing, Marker, Derivative Assay

Journal: Nature Communications

Article Title: In situ self-assembled cell reservoir hydrogel for maneuvering multistage radioimmunotherapy

doi: 10.1038/s41467-026-68490-5

Figure Lengend Snippet: a Schematic illustration showing immunosuppression within the TME after monotherapy of RT. b Representative flow cytometry plots and corresponding quantification of CTLA-4 expression in CD3 + T cells within tumors from orthotopic 4T1 tumor-bearing mice at 24 h post the treatments of saline and RT. c , d Representative flow cytometry plots ( c ) and quantifications of CD3 + CD8 + T cells, CD4 + CD25 + T cells, and the ratio of CD8 + T/Treg ( d ) in tumors from orthotopic 4T1 tumor-bearing mice at 24 h. e – g Quantification of CD8 + T cells ( e ), NK cells ( f ), and Tregs ( g ) in orthotopic 4T1 tumors after different treatments. h – j Quantification of IFN-γ production by CD8 + T cells ( h ), CD4 + T cells ( i ), and NK cells ( j ). k Quantification of mature DC (CD80 + CD86 + in CD11c + MHC Ⅱ + cells) in orthotopic 4T1 tumors after different treatments. l – n Quantitative analyses of cDC1 ( l ) and cDC2 ( m ) and activated CD8 + T lymphocytes (CD69 + in CD3 + CD8 + cells) ( n ) in TDLNs of orthotopic 4T1 tumor-bearing mice post different treatments. o Schematic for the tumor rechallenge model establishment and RT + IL/aC@RBAH-mediated therapeutic procedure. p Average tumor growth curves of subcutaneous rechallenge mice receiving the RT + IL/aC@RBAH treatment. Healthy mice implanted with 4T1 tumor cells on day 26 were indicated as control. q Quantification of Tem cells (CD62L − CD44 + ) and ratios of Tcm/Tem cells gating on CD8 + T cells and CD4 + T cells in spleens of 4T1 tumor-bearing mice at the end of different treatments. G1, Saline; G2, RT; G3, RT + RBAH; G4, RT + aC@RBAH; G5, RT + IL@RBAH; G6, RT + IL/aC@RBAH. Experiments in ( b , c ) were independently repeated three times with comparable results. Data in ( b , d – n , p , q ) were presented as mean ± SD. n = 3 mice per group were used in ( b , d – n , q ). n = 5 mice per group were used in ( p ). Statistical significance was determined using two-sided unpaired student’s t -test ( b , d – n , q ) and two-way ANOVA ( p ). Source data are provided as a Source Data file.

Article Snippet: InVivoMAb anti-mouse CTLA-4 (CD152) antibody (Cat# BE0131, Bio X Cell) was purchased from BioXcell.

Techniques: Flow Cytometry, Expressing, Saline, Control